Senseonics Holdings, Inc. 8-K

What Happened
Senseonics Holdings, Inc. (SENS) announced on May 1, 2026 that it entered a Second Amendment to its Loan and Security Agreement with Hercules Capital as agent and other lenders. The amended agreement makes up to $140.0 million in senior secured term loans available to Senseonics, consisting of the previously funded $35.0 million initial term loan, a $10.0 million Tranche 2 loan to be funded at the amendment closing (scheduled May 6, 2026), and additional tranches (Tranche 3A $10.0M, Tranche 3B $10.0M, Tranche 4 $15.0M and an uncommitted Tranche 5 up to $60.0M) that become available if specified conditions are met. Loans mature on September 3, 2029.

Key Details

• Total facility up to $140.0M; $35.0M already funded; Tranche 2 ($10M) and Tranche 3A ($10M) expected to fund at the May 6, 2026 closing, subject to conditions.
• Interest: greater of (i) Prime (WSJ) + 2.40% or (ii) 9.90% annual.
• Payments: monthly interest‑only through October 1, 2028 (and potentially through the Maturity Date if a 2025 milestone is met); thereafter equal monthly principal+interest payments until Sept 3, 2029.
• Fees & prepayment: $100,000 facility fee and $100,000 amendment fee due at closing; additional facility fees of 0.50% (Tranche 3B) or 1.00% (Tranche 4/5) on draws; prepayment fee of 3.0% (year 1), 2.0% (year 2), 1.0% (after year 2).
• Equity kicker: Senseonics will issue additional warrants on funding of each tranche. Warrants equal an aggregate 2.0% of the funded loan amount (shares calculated using a 3‑day VWAP) and are exercisable up to seven years, subject to customary adjustments.

Why It Matters
This amendment gives Senseonics expanded committed and contingent liquidity that can extend its operating runway but does so by adding senior secured debt and dilutive warrants. Investors should note the relatively high effective interest floor (9.90% minimum), ongoing fees, and prepayment penalties that increase borrowing costs. Future funding beyond the committed tranches depends on meeting contract milestones, and warrant issuance creates potential equity dilution if exercised. Monitor the company’s subsequent 10‑Q and disclosures for the executed amendment, actual tranche drawdowns, milestone progress, and the impact on cash runway and capital structure.